IDT Australia Ltd
IDT Australia Limited is a pharmaceutical manufacturing company.
The business
IDT Australia Limited is a pharmaceutical manufacturing company. The Company is engaged in the supply of products and provision of research and development and other technical services within the pharmaceutical and allied industries. Its business includes research and development, active pharmaceutical ingredient (API) and finished dosage form manufacture (FDF), clinical and commercial, project management, chemical services, analytical chemistry, pharmacy services, pharmaceutical development in all dosage forms, clinical packaging and regulatory affairs services. Its Current Good Manufacturing Practice (cGMP) manufacturing facilities produces both API and FDF across the medicinal cannabis manufacturing space. It also provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms. Its analytical laboratories offer medicinal cannabis cGMP testing.
Small Caps Research
No research on IDT Australia Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise IDT based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
IDT Australia Reports Operational Improvements with New Leadership Team and Realignment Strategy
IDT Australia (ASX: IDT) reports improving six-month ops under a new leadership team and realignment strategy; revenue up 20% to $8.4m, EBITDA losses narrowed.
IDT Australia to pioneer national ADC manufacturing with Victorian government grant
Pharmaceutical manufacturing company IDT Australia (ASX: IDT) has been awarded a grant by the Victoria state government to partly fund the establishment of Australia’s first current good manufacturing practice antibody-drug-conjugate (ADC) manufacturing facility. The grant, provided by the Victorian Industry Investment Fund stream of the Victorian Jobs and Investment Fund, will support IDT Australia’s new […]
Cann to supply medicinal cannabis products to EU and UK, IDT will manufacture
Australian cannabis developer Cann Group (ASX: CAN) has signed two agreements for the supply of medicinal cannabis-formulated oil and dried flower products to markets in the United Kingdom and European Union. The first deal is with UK-based Astral Health for the supply of oils including high THC (tetrahydrocannabinol), high CBD (cannabidiol) and a balanced formulation […]
Cann Group and IDT Australia move closer to bringing medicinal cannabis products to market
Cann Group (ASX: CAN) and IDT Australia (ASX: IDT) are closer to producing their first medicinal cannabis products with GMP extraction activities now underway. Once extracted, the resin will be used as an active pharmaceutical ingredient for either purchase or to produce GMP medicinal cannabis oil products at IDT’s facilities. The next step for the […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.